KAT-681 | CAS#373641-87-3 | thyromimetic

MedKoo Cat#: 558133 | Name: KAT-681

Description:

WARNING: This product is for research use only, not for human or veterinary use.

KAT-681 is a liver-selective thyromimetic.

Chemical Structure

KAT-681

CAS#373641-87-3

Theoretical Analysis

MedKoo Cat#: 558133

Name: KAT-681

CAS#: 373641-87-3

Chemical Formula: C24H21FNNaO6

Exact Mass:

Molecular Weight: 461.42

Elemental Analysis: C, 62.47; H, 4.59; F, 4.12; N, 3.04; Na, 4.98; O, 20.80

Price and Availability

This product is currently not in stock but may be available through custom synthesis. To ensure cost efficiency, the minimum order quantity is 1 gram. The estimated lead time is 2 to 4 months, with pricing dependent on the complexity of the synthesis (typically high for intricate chemistries). Quotes for quantities below 1 gram will not be provided. To request a quote, please click the button below. Note: If this product becomes available in stock in the future, pricing will be listed accordingly.

Bulk Inquiry

Related CAS #

No Data

Synonym

T 0681; T-0681; T0681;

IUPAC/Chemical Name

Propanoic acid, 3-((4-(3-((4-fluorophenyl)hydroxymethyl)-4-hydroxyphenoxy)-3,5-dimethylphenyl)amino)-3-oxo-, monosodium salt

InChi Key

WIAUUVBWUTVDDD-UHFFFAOYSA-M

InChi Code

InChI=1S/C24H22FNO6.Na/c1-13-9-17(26-21(28)12-22(29)30)10-14(2)24(13)32-18-7-8-20(27)19(11-18)23(31)15-3-5-16(25)6-4-15;/h3-11,23,27,31H,12H2,1-2H3,(H,26,28)(H,29,30);/q;+1/p-1

SMILES Code

O=C([O-])CC(NC1=CC(C)=C(OC2=CC=C(O)C(C(C3=CC=C(F)C=C3)O)=C2)C(C)=C1)=O.[Na+]

Appearance

Solid powder

Purity

>98% (or refer to the Certificate of Analysis)

Shipping Condition

Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition

Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility

Soluble in DMSO

Shelf Life

>2 years if stored properly

Drug Formulation

This drug may be formulated in DMSO

Stock Solution Storage

0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code

2934.99.9001

More Info

Instruction

View handling instruction

Preparing Stock Solutions

The following data is based on the product molecular weight 461.42 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Concentration / Solvent Volume / Mass	1 mg	5 mg	10 mg
1 mM	1.15 mL	5.76 mL	11.51 mL
5 mM	0.23 mL	1.15 mL	2.3 mL
10 mM	0.12 mL	0.58 mL	1.15 mL
50 mM	0.02 mL	0.12 mL	0.23 mL

1: Hayashi M, Ohnota H, Tamura T, Kuroda J, Shibata N, Akahane M, Moriwaki H, Machida N, Mitsumori K. Inhibitory effects of KAT-681, a liver-selective thyromimetic, on development of hepatocellular proliferative lesions in rats induced by 2-acetylaminofluorene and partial hepatectomy after diethylnitrosamine initiation. Arch Toxicol. 2004 Aug;78(8):460-6. Epub 2004 Mar 19. PubMed PMID: 15034639. 2: Hayashi M, Tamura T, Kuroda J, Ohnota H, Shibata N, Akahane M, Kashida Y, Mitsumori K. Different inhibitory effects in the early and late phase of treatment with KAT-681, a liver-selective thyromimetic, on rat hepatocarcinogenesis induced by 2-acetylaminofluorene and partial hepatectomy after diethylnitrosamine initiation. Toxicol Sci. 2005 Mar;84(1):22-8. Epub 2004 Nov 24. PubMed PMID: 15564315. 3: Tancevski I, Eller P, Patsch JR, Ritsch A. The resurgence of thyromimetics as lipid-modifying agents. Curr Opin Investig Drugs. 2009 Sep;10(9):912-8. Review. PubMed PMID: 19705333; PubMed Central PMCID: PMC2993058. 4: Tancevski I, Wehinger A, Demetz E, Hoefer J, Eller P, Huber E, Stanzl U, Duwensee K, Auer K, Schgoer W, Kuhn V, Fievet C, Stellaard F, Rudling M, Foeger B, Patsch JR, Ritsch A. The thyromimetic T-0681 protects from atherosclerosis. J Lipid Res. 2009 May;50(5):938-44. doi: 10.1194/jlr.M800553-JLR200. Epub 2008 Dec 22. PubMed PMID: 19106072; PubMed Central PMCID: PMC2666180. 5: Tancevski I, Demetz E, Eller P, Duwensee K, Hoefer J, Heim C, Stanzl U, Wehinger A, Auer K, Karer R, Huber J, Schgoer W, Van Eck M, Vanhoutte J, Fievet C, Stellaard F, Rudling M, Patsch JR, Ritsch A. The liver-selective thyromimetic T-0681 influences reverse cholesterol transport and atherosclerosis development in mice. PLoS One. 2010 Jan 15;5(1):e8722. doi: 10.1371/journal.pone.0008722. PubMed PMID: 20090943; PubMed Central PMCID: PMC2806908.